Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Vicki Sato
AddedMar 31, 2024
UpdatedMay 31, 2026
Vicki Sato

Vicki Sato

Board Member, Allogene Therapeutics

Crunchbase

Vicki Sato's Career

Allogene Therapeutics
Allogene Therapeutics

South San Francisco, CA, US

Board Member· Board
Denali Therapeutics
Denali Therapeutics

San Francisco, CA, US

Board Member· Board
Vir Biotechnology
Vir Biotechnology

San Francisco, CA, US

Board Member· Board
Bristol Myers Squibb
Bristol Myers Squibb

New York City, NY, US

Board Member· Board
Vaxess Technologies
Vaxess Technologies

Cambridge, MA, US

Board Member· Board
Aera Therapeutics
Aera Therapeutics

Boston, MA, US

Board Member· Board
Nimbus Therapeutics
Nimbus Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Vicki Sato's Career

Allogene Therapeutics
Allogene Therapeutics
Public$781.8M3612017South San Francisco, CA, US
Board Member· Board

Leadership at Allogene Therapeutics

David ChangDavid ChangFounder
Liz BarrettLiz BarrettBoard Member
Stephen L. MayoStephen L. MayoBoard Member
Debbie MessemerDebbie MessemerBoard Member
Owen WitteOwen WitteBoard Member
John DeYoungJohn DeYoungBoard Member
Denali Therapeutics
Denali Therapeutics
Public$622M4272015San Francisco, CA, US
Board Member· Board

Leadership at Denali Therapeutics

Jennifer CookJennifer CookBoard Member
Tom StockyTom StockyBoard Member
Steve KrognesSteve KrognesBoard Member
Jay FlatleyJay FlatleyBoard Member
David SchenkeinDavid SchenkeinBoard Member
Marc Tessier-LavigneMarc Tessier-LavigneBoard Member
Vir Biotechnology
Vir Biotechnology
Public$908.6M5762016San Francisco, CA, US
Board Member· Board

Leadership at Vir Biotechnology

Phillip A. SharpPhillip A. SharpBoard Member
Elliott SigalElliott SigalBoard Member
Rob PerezRob PerezBoard Member
Louis PickerLouis PickerCo-Founder
Klaus FruehKlaus FruehCo-Founder
Kristina BurowKristina BurowBoard Member

Similar to Vir Biotechnology

Virion TherapeuticsVirion TherapeuticsNewark, DE, USImmunotherapy, Vaccinesest. 2018Virion TherapeuticsNewark, DE, US · est. 2018

Virion Therapeutics: A global biotech firm innovating vaccines for cancers and chronic viral infections.

Series B · $14.1M8
ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
Precision VirologicsPrecision VirologicsSt. Louis, MO, USBiotechest. 2016Precision VirologicsSt. Louis, MO, US · est. 2016

Precision Virologics: A St. Louis-based biotech startup innovating in virology.

Angel · $1M6
TherabiolTherabiolSan Francisco, CA, USImmune Therapiesest. 2012TherabiolSan Francisco, CA, US · est. 2012

Therabiol, Inc.: A San Francisco-based biotech firm specializing in developing immune therapies for viral infections.

Seed · $150k5
Bristol Myers Squibb
Bristol Myers Squibb
Public$10.6B34.3k1887New York City, NY, US
Board Member· Board

Leadership at Bristol Myers Squibb

William McLaren BristolWilliam McLaren BristolCo-Founder
E. R. SquibbE. R. SquibbCo-Founder
Giovanni CaforioGiovanni CaforioBoard Member
Deepak L. BhattDeepak L. BhattBoard Member
Paula A. PricePaula A. PriceBoard Member
Douglas KouDouglas KouBoard Member

Similar to Bristol Myers Squibb

Bayer PharmaceuticalsBayer PharmaceuticalsBerlin, Berlin, DEDrugs, Pharmaceuticalsest. 2003Bayer PharmaceuticalsBerlin, Berlin, DE · est. 2003

Bayer Pharmaceuticals: A global enterprise specializing in biochemical research and drug manufacturing since 2008.

Public10k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Eli Lilly and CompanyEli Lilly and CompanyPharmaceuticalsest. 1876Eli Lilly and Companyest. 1876

Global pharmaceutical innovator for humans and animals. Pioneering neuroscience, endocrine, oncology, and animal health solutions.

Public39k
GSKGSKLondon, Greater London, GBBiotech, Pharmaceuticalsest. 2000GSKLondon, Greater London, GB · est. 2000

GSK PLC: A British multinational firm innovating in pharmaceuticals, biotech, and health products.

Public · $25.5M69.4k
Vaxess Technologies
Vaxess Technologies
Series A$74.9M422011Cambridge, MA, US
Board Member· Board

Leadership at Vaxess Technologies

Kathryn KosudaKathryn KosudaCo-Founder
Michael SchraderMichael SchraderCo-Founder
Livio ValentiLivio ValentiCo-Founder
Aaron SandoskiAaron SandoskiBoard Member
Purnanand SarmaPurnanand SarmaBoard Member
Patrick HoPatrick HoCo-Founder
Aera Therapeutics
Aera Therapeutics
Series B$193M1752021Boston, MA, US
Board Member· Board

Leadership at Aera Therapeutics

Akin AkincAkin AkincBoard Member

Similar to Aera Therapeutics

Aro BiotherapeuticsAro BiotherapeuticsPhiladelphia, PA, USGenetic Medicinesest. 2018Aro BiotherapeuticsPhiladelphia, PA, US · est. 2018

Aro Biotherapeutics: Pioneering tissue-targeted genetic medicines via proprietary Centyrin technology.

Series B · $166.5M48
Affinia TherapeuticsAffinia TherapeuticsWaltham, MA, USGene Therapiesest. 2019Affinia TherapeuticsWaltham, MA, US · est. 2019

Affinia Therapeutics: A biotech firm innovating gene therapies for muscle and CNS diseases.

Series B · $170M75
Alaya.bioAlaya.bioCambridge, MA, USGene Delivery, Immunotherapyest. 2022Alaya.bioCambridge, MA, US · est. 2022

Alaya.bio, a Cambridge-based software company, pioneers in situ gene delivery and CAR T cell immunotherapy.

Pre-Seed · $3M30
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
Nimbus Therapeutics
Nimbus Therapeutics
Public$637M1122009Cambridge, MA, US
Board Member· Board

Leadership at Nimbus Therapeutics

Mark IwickiMark IwickiBoard Member
Laura StoppelLaura StoppelBoard Member
Anne McGeorgeAnne McGeorgeBoard Member
Bruce BoothBruce BoothBoard Member
Steve HallSteve HallBoard Member
Ramy FaridRamy FaridBoard Member

Similar to Nimbus Therapeutics

NGM BiopharmaceuticalsNGM BiopharmaceuticalsSouth San Francisco, CA, USTherapeuticsest. 2007NGM BiopharmaceuticalsSouth San Francisco, CA, US · est. 2007

NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.

Public · $420.4M225
Nirogy TherapeuticsNirogy TherapeuticsNatick, MA, USDrug Developmentest. 2013Nirogy TherapeuticsNatick, MA, US · est. 2013

Nirogy Therapeutics: Innovating small molecule drugs to target cellular transporters and disrupt tumor growth.

Series A · $18.5M16
Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30

Vicki Sato's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Vicki Sato

Tillman GerngrossTillman GerngrossBoard Member · AlectorTyler JacksTyler JacksCo-Founder · T2 BiosystemsJonathan RothbergJonathan RothbergBoard Member · 4CatalyzerPamela SilverPamela SilverCo-Founder · 64x BioGerald FinkGerald FinkCo-Founder · BoragenJay KeaslingJay KeaslingCo-Founder · Demetrix